Vadastuximab talirine
Vadastuximab talirine is an antibody-drug conjugate (ADC) designed for the treatment of acute myeloid leukemia (AML). It is composed of a monoclonal antibody targeting the CD33 antigen, which is commonly expressed on the surface of AML cells, linked to a cytotoxic agent.
Mechanism of Action[edit | edit source]
Vadastuximab talirine works by specifically binding to the CD33 antigen on the surface of AML cells. Upon binding, the ADC is internalized into the cell, where the cytotoxic agent is released. This agent then induces DNA damage, leading to cell death. The targeted approach aims to minimize damage to normal, healthy cells, thereby reducing the side effects typically associated with conventional chemotherapy.
Development and Clinical Trials[edit | edit source]
Vadastuximab talirine was developed by Seattle Genetics. It has undergone various phases of clinical trials to evaluate its safety and efficacy in patients with AML. The results from these trials have been mixed, with some showing promising outcomes in terms of remission rates and overall survival, while others have raised concerns about potential side effects and toxicity.
Side Effects[edit | edit source]
Common side effects of vadastuximab talirine include neutropenia, thrombocytopenia, and anemia. More severe side effects can include hepatotoxicity and veno-occlusive disease (VOD). Due to these potential risks, the use of vadastuximab talirine is typically reserved for patients who have not responded to other treatments or who are ineligible for other forms of therapy.
Current Status[edit | edit source]
As of the latest updates, vadastuximab talirine is not yet approved by the Food and Drug Administration (FDA) for general use. Ongoing research and additional clinical trials are being conducted to further assess its safety and efficacy.
Related Pages[edit | edit source]
- Acute myeloid leukemia
- Antibody-drug conjugate
- CD33
- Seattle Genetics
- Chemotherapy
- Neutropenia
- Thrombocytopenia
- Anemia
- Hepatotoxicity
- Veno-occlusive disease
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
